Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field.